CD28null T cells in aging and diseases: From biology to assessment and intervention.

• CD28null T cells exhibit unique characteristics and may play pivotal physiological roles in aging and disease. • This article highlights the potential of CD28null T cells as immunological biomarkers by emphasizing their significant association with age, disease progression, and prognosis. • This review speculates that targeting CD28null T cells represents a promising approach to delay the aging process and prevent or attenuate disease progression. CD28null T cells, an atypical subset characterized by the loss of CD28 costimulatory molecule expression, exhibit functional variants and progressively expand with age. Moreover, T cells with these phenotypes are found in both typical and atypical humoral immune responses. Consequently, they accumulate during infectious diseases, autoimmune disorders, cardiovascular conditions, and neurodegenerative ailments. To provide an in-depth review of the current knowledge regarding CD28null T cells, we specifically focus on their phenotypic and functional characteristics as well as their physiological roles in aging and diseases. While uncertainties regarding the clinical utility remains, we will review the following two crucial research perspectives to explore clinical translational applications of the research on this specific T cell subset: 1) addressing the potential utility of CD28null T cells as immunological markers for prognosis and adverse outcomes in both aging and disease, and 2) speculating on the potential of targeting CD28null T cells as an interventional strategy for preventing or delaying immune aging processes and disease progression. [ABSTRACT FROM AUTHOR]